These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35841237)

  • 41. Alzheimer's Disease: Advances in Drug Development.
    Piton M; Hirtz C; Desmetz C; Milhau J; Lajoix AD; Bennys K; Lehmann S; Gabelle A
    J Alzheimers Dis; 2018; 65(1):3-13. PubMed ID: 30040716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Editorial. BACE or beta-secretase -a target for drug discovery for treatment of Alzheimer's disease.
    Dunn BM
    Protein Pept Lett; 2008; 15(2):118. PubMed ID: 18289103
    [No Abstract]   [Full Text] [Related]  

  • 43. Editorial: Combining Forces to Improve Alzheimer's Disease Drug Discovery: The Symptomatic Battle.
    Deguil J; Auffret A; Schenker E; Aujard F; Lamberty Y; Bartrès-Faz D; Blin O; Micallef J; Richardson JC; Bordet R
    CNS Neurol Disord Drug Targets; 2016; 15(7):754-5. PubMed ID: 27549167
    [No Abstract]   [Full Text] [Related]  

  • 44. Development of tau-directed small molecule modulators for Alzheimer's disease: a recent patent review (2014-2018).
    Lee HE; Lim D; Lee JY; Lim SM; Pae AN
    Pharm Pat Anal; 2019 Jan; 8(1):15-39. PubMed ID: 30870110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions.
    Abeysinghe AADT; Deshapriya RDUS; Udawatte C
    Life Sci; 2020 Sep; 256():117996. PubMed ID: 32585249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The "rights" of precision drug development for Alzheimer's disease.
    Cummings J; Feldman HH; Scheltens P
    Alzheimers Res Ther; 2019 Aug; 11(1):76. PubMed ID: 31470905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toward Bridging Unmet Medical Need in Early Alzheimer's Disease: An Evaluation of Beta-Amyloid (Aβ) Plaque Burden as a Potential Drug Development Tool.
    Zhu H; Mehta M; Huang SM; Wang Y
    Clin Pharmacol Ther; 2022 Apr; 111(4):728-731. PubMed ID: 35187648
    [No Abstract]   [Full Text] [Related]  

  • 48. Editorial: Alzheimer's Disease - Mechanisms, Drug Targets and Alternative Treatments.
    Hua Q; He R
    Curr Top Med Chem; 2016; 16(5):470-1. PubMed ID: 26279184
    [No Abstract]   [Full Text] [Related]  

  • 49. Alzheimer's disease: clinical trials and drug development.
    Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M
    Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug development status for Alzheimer's disease: present scenario.
    Misra S; Medhi B
    Neurol Sci; 2013 Jun; 34(6):831-9. PubMed ID: 23392897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation.
    Liu Y; Cong L; Han C; Li B; Dai R
    Mini Rev Med Chem; 2021; 21(8):969-990. PubMed ID: 33245270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug development for Alzheimer's disease: review.
    Lao K; Ji N; Zhang X; Qiao W; Tang Z; Gou X
    J Drug Target; 2019 Feb; 27(2):164-173. PubMed ID: 29732929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.
    Kramer LD
    J Prev Alzheimers Dis; 2020; 7(3):142-143. PubMed ID: 32463064
    [No Abstract]   [Full Text] [Related]  

  • 54. Editorial (Thematic Issue: Current and Perspective Therapeutic Strategies for Alzheimer's Disease).
    Piccionello AP; Cappello F
    Curr Pharm Des; 2016; 22(26):3935-6. PubMed ID: 27535701
    [No Abstract]   [Full Text] [Related]  

  • 55. Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug Development.
    Gayathri S; Raghu CH; Fayaz SM
    CNS Neurol Disord Drug Targets; 2022; 21(5):409-426. PubMed ID: 34544351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in developing novel therapeutic strategies for Alzheimer's disease.
    Cao J; Hou J; Ping J; Cai D
    Mol Neurodegener; 2018 Dec; 13(1):64. PubMed ID: 30541602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy.
    Jun H; Cho SK; Aliyev ER; Mattke S; Suen SC
    Curr Alzheimer Res; 2020; 17(9):819-822. PubMed ID: 33272181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification.
    Hampel H; Vergallo A; Giorgi FS; Kim SH; Depypere H; Graziani M; Saidi A; Nisticò R; Lista S;
    Front Neuroendocrinol; 2018 Jul; 50():31-51. PubMed ID: 29902481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Editorial: Small molecule therapeutics for Alzheimer's disease.
    Ma DL; Leung CH
    Curr Alzheimer Res; 2015; 12(5):400-2. PubMed ID: 26017557
    [No Abstract]   [Full Text] [Related]  

  • 60. [Drug therapy of Alzheimer's disease. Problems and strategy in development of new therapeutic drugs for Alzheimer's disease].
    Moroji T; Matsuzaki I
    Nihon Rinsho; 1988 Jul; 46(7):1586-91. PubMed ID: 2906096
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.